# Immix因AL類澱粉樣變性療法中期試驗數據上漲。

*biotech · news · 2026-05-21 · Seeking Alpha*

## Key points

- Immix Biopharma公布NXC-201用於AL類澱粉樣變性的中期試驗數據。
- NXC-201正在測試一種涉及異常輕鏈堆積的罕見疾病。
- 公告發布後，Immix Biopharma股價上漲。
- 公告中未披露中期試驗數據的具體細節。

Immix rises after mid-stage trial data for AL amyloidosis therapy May 21, 2026, 7:02 AM ETImmix Biopharma, Inc. (IMMX) StockBy : Dulan Lokuwithana, SA News Editor Comment (1) Immix Biopharma (IMMX) traded higher after announcing data from a mid-stage trial for its lead asset, NXC-201, in AL amyloidosis, a rare disease characterized by the accumulation of abnormal light chains in various organs of the body. The company said Newsletters for Every Investor Get daily, sector-specific newsletters packed with expert insights, fresh ideas, and new opportunities. Subscribe to Newsletters

[Read the full story on Seeking Alpha](https://seekingalpha.com/news/4595696-immix-rises-data-al-amyloidosis-therapy)

---

Canonical: https://newsio.io/zh-TW/n/2a3c5859-09b9-4b94-85ae-62bd356fd4e1/immixal
Summarized by Newsio from Seeking Alpha. https://newsio.io/how-it-works